Eli Lilly's Antibody Cocktails Could Run Out

    Two days ago, President Trump spoke to the American people from outside the Oval Office about his medical experience in dealing with the Coronavirus.  While he was at Walter Reed Military Hospital, he received two therapeutic antibody cocktails: one from Eli Lilly, and the other from Regeneron.  The therapeutics from those two companies are now set to be approved so those drug companies can market and sell them.

As a blogger for Eli Lilly, I have noticed that in accordance with Trump's wishes for a low-cost medical dose, combined with Eli Lilly's philanthropic tendency, I expect deep discounts in the Lilly cocktail's price.  However, in my coverage of news about the progress of the antibody medicine, I have seen footage of Lilly's CEO speaking about how difficult the antibodies are to produce.  The point I am trying to make is that maybe a high-cost quantity should be held in reserve so that those who have the money to buy the cocktails can do so before the supply runs out.

Paul Wharton

Special thanks to Eli Lilly & Co. (LLY) for inventing the fuel of my mind